J. L. Abbruzzese

1.1k total citations
51 papers, 905 citations indexed

About

J. L. Abbruzzese is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. L. Abbruzzese has authored 51 papers receiving a total of 905 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 15 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. L. Abbruzzese's work include Pancreatic and Hepatic Oncology Research (20 papers), Colorectal Cancer Treatments and Studies (18 papers) and Cancer Genomics and Diagnostics (10 papers). J. L. Abbruzzese is often cited by papers focused on Pancreatic and Hepatic Oncology Research (20 papers), Colorectal Cancer Treatments and Studies (18 papers) and Cancer Genomics and Diagnostics (10 papers). J. L. Abbruzzese collaborates with scholars based in United States, Japan and Australia. J. L. Abbruzzese's co-authors include Jaffer A. Ajani, Philip Frost, Robert A. Wolff, Renato Lenzi, B. Levin, Richard Pazdur, Qinghua Xiong, Qian Shi, Martin N. Raber and Xiangdong Le and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. L. Abbruzzese

48 papers receiving 890 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. L. Abbruzzese United States	17	636	309	174	173	126	51	905
Alberto Comino Italy	11	430 0.7×	319 1.0×	85 0.5×	118 0.7×	140 1.1×	20	704
Bin Meng China	18	334 0.5×	245 0.8×	186 1.1×	141 0.8×	152 1.2×	62	814
William H. Isacoff United States	16	499 0.8×	152 0.5×	223 1.3×	146 0.8×	227 1.8×	25	804
Jene Choi South Korea	17	329 0.5×	332 1.1×	335 1.9×	202 1.2×	129 1.0×	32	930
Carmen Nuzzo Italy	14	481 0.8×	403 1.3×	312 1.8×	189 1.1×	124 1.0×	31	1.0k
Bunzo Nakata Japan	16	667 1.0×	344 1.1×	201 1.2×	254 1.5×	245 1.9×	70	977
Ho-Yeong Lim South Korea	17	345 0.5×	301 1.0×	308 1.8×	140 0.8×	173 1.4×	31	863
M. Paganuzzi Italy	16	331 0.5×	257 0.8×	518 3.0×	99 0.6×	115 0.9×	38	992
Dulabh Monga United States	15	539 0.8×	396 1.3×	227 1.3×	119 0.7×	277 2.2×	74	1.1k
A. Reinacher-Schick Germany	11	441 0.7×	175 0.6×	146 0.8×	149 0.9×	93 0.7×	46	636

Countries citing papers authored by J. L. Abbruzzese

Since Specialization

Citations

This map shows the geographic impact of J. L. Abbruzzese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. L. Abbruzzese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. L. Abbruzzese more than expected).

Fields of papers citing papers by J. L. Abbruzzese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. L. Abbruzzese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. L. Abbruzzese. The network helps show where J. L. Abbruzzese may publish in the future.

Co-authorship network of co-authors of J. L. Abbruzzese

This figure shows the co-authorship network connecting the top 25 collaborators of J. L. Abbruzzese. A scholar is included among the top collaborators of J. L. Abbruzzese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. L. Abbruzzese. J. L. Abbruzzese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reddy, Sangeetha M., Scott Kopetz, Jeffrey S. Morris, et al.. (2015). Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs. 33(4). 977–984. 33 indexed citations

Javle, M. M., Gauri R. Varadhachary, David R. Fogelman, et al.. (2011). Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer.. Journal of Clinical Oncology. 29(15_suppl). 4026–4026. 15 indexed citations

Javle, M. M., Gauri R. Varadhachary, Rachna T. Shroff, et al.. (2010). Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer.. Journal of Clinical Oncology. 28(15_suppl). 4039–4039. 15 indexed citations

Lieu, Christopher H., Robert A. Wolff, Cathy Eng, et al.. (2010). Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer.. Journal of Clinical Oncology. 28(15_suppl). 3536–3536. 8 indexed citations

Overman, Michael J., Gauri R. Varadhachary, Emily Lin, et al.. (2008). Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater. Journal of Clinical Oncology. 26(15_suppl). 4538–4538. 3 indexed citations

Soliman, Amr S., Xiaolei Wang, Melissa L. Bondy, et al.. (2006). Geographical Clustering of Pancreatic Cancers in the Northeast Nile Delta Region of Egypt. Archives of Environmental Contamination and Toxicology. 51(1). 142–148. 26 indexed citations

Ellis, Lee M., M. OʼReilly, LM Ho, et al.. (2004). RhuMab VEGF (bevacizumab) with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer: An active, well tolerated regimen. International Journal of Radiation Oncology*Biology*Physics. 60. S149–S149.

Yao, James C., Chusilp Charnsangavej, Silvana C. Faria, et al.. (2004). Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab. Journal of Clinical Oncology. 22(14_suppl). 3013–3013. 5 indexed citations

Whitehead, Robert P., et al.. (2004). A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study. Journal of Clinical Oncology. 22(14_suppl). 4012–4012. 13 indexed citations

10.

Abbruzzese, J. L., et al.. (2002). Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Seminars in Oncology. 29(5). 31–37. 92 indexed citations

11.

Kuniyasu, Hiroki, J. L. Abbruzzese, K. Cleary, & Isaiah J. Fidler. (2001). Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. International Journal of Oncology. 19(4). 681–5. 39 indexed citations

12.

Tseng, Jennifer, Bonnie S. Glisson, Fadlo R. Khuri, et al.. (2001). Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 92(9). 2364–2373. 40 indexed citations

13.

Raijman, Isaac, Iqbal Siddique, Jaffer A. Ajani, et al.. (1998). Palliation of malignant gastric outlet and duodenal obstruction using expandable metallic stents. Gastrointestinal Endoscopy. 47(4). 2 indexed citations

14.

Evans, Douglas B., Jeffrey E. Lee, Peter W. T. Pisters, et al.. (1997). Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer treatment and research. 90. 109–125. 31 indexed citations

15.

Pazdur, Richard, J. L. Abbruzzese, Avi B. Markowitz, et al.. (1995). Phase II Trial of Isotretinoin and Recombinant Interferon Alfa-2a in Metastatic Colorectal Carcinoma. American Journal of Clinical Oncology. 18(5). 436–438. 2 indexed citations

16.

Pazdur, Richard, Yvonne Lassere, Jaffer A. Ajani, et al.. (1994). Phase II trial of docetaxel (Taxotere®) in metastatic colorectal carcinoma. Annals of Oncology. 5(5). 468–470. 44 indexed citations

17.

Abbruzzese, J. L., et al.. (1992). Studies on the mechanism of the synergistic interaction between 2?-deoxy-5-azacytidine and cisplatin. Cancer Chemotherapy and Pharmacology. 30(1). 31–36. 17 indexed citations

18.

Frost, Philip, et al.. (1990). Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.. PubMed. 50(15). 4572–7. 31 indexed citations

19.

Abbruzzese, J. L., Denis Gravel, Ronelle A. DuBrow, et al.. (1989). Phase I Trial of Semustine Plus Weekly Fluorouracil and High-Dose Leucovorin Calcium in Patients With Advanced Colorectal Cancer. JNCI Journal of the National Cancer Institute. 81(23). 1840–1842. 2 indexed citations

20.

Ajani, Jaffer A., J. L. Abbruzzese, J Faintuch, et al.. (1988). Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.. Journal of Clinical Oncology. 6(11). 1703–1707. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact